Intellia Therapeutics Report issue

For profit Phase 2 Phase 3
Founded: Cambridge MA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04601051
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Intellia Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

ntla-2001 (2 trials)

Drugs in Phase 2 Trials (2)

ntla-2002 (1 trial)

ntla-5001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloid Neuropathies, Familial (Phase 1)

Amyloidosis (Phase 1)

Polyneuropathies (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3